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In established tumors, angiogenic endothelial cells (ECs) coexist next to “quiescent” EC in matured vessels. We hypothesized that
angio-gene expression of B16.F10 melanoma would diﬀer depending on the growth stage. Unraveling the spatiotemporal nature
thereof is essential for drug regimen design aimed to aﬀect multiple neovascularization stages. We determined the angiogenic
phenotype—represented by 52 angio-genes—and vascular morphology of small, intermediate, and large s.c. growing mouse
B16.F10 tumors and demonstrated that expression of these genes did not diﬀer between the diﬀerent growth stages. Yet vascular
morphology changed dramatically from small vessels without lumen in small to larger vessels with increased lumen size in
intermediate/large tumors. Separate analysis of these vascular morphologies revealed a signiﬁcant diﬀerence in αSMA expression
in relation to vessel morphology, while no relation with VEGF, HIF-1α, nor Dll4 expression levels was observed. We conclude that
the tumor vasculature remains actively engaged in angiogenesis during B16.F10 melanoma outgrowth and that the major change
in tumor vascular morphology does not follow molecular concepts generated in other angiogenesis models.
1.Introduction
Tumors depend on the recruitment of new blood vessels to
growbeyondacertainsizeandtometastasizetoothertissues.
This process represents an attractive target for the treatment
of cancer, and several strategies have been pursued to inhibit
neovascularization [1]. Yet, antiangiogenic drugs in clinical
trials have not fully lived up to their expectations [2, 3].
The limited eﬃcacy of antiangiogenic therapies may ﬁnd its
origin in heterogeneity of the molecular activation status of
endothelial cells in the tumor vasculature [4, 5]. More than
ten years ago, Bergers et al. demonstrated that the eﬃcacy
of antiangiogenic drugs in a multistage carcinogenesis model
depends on the tumor growth stage being targeted [6].
Additional evidence for diﬀerential susceptibility of tumor
vasculature to antiangiogenic treatment was given by Wood
etal.[7].They showed that inhibition of vascularendothelial
growth factor- (VEGF-) receptor 2 caused a reduced occur-
rence of microvessels in the interior of the tumor, while
larger, more mature vessels remained unaﬀected [7].
We hypothesize that the tumor growth stage-speciﬁc
responses to antiangiogenic drugs are related to the exis-
tence of diﬀerences in angiogenic status of the tumor
microvasculature in the diﬀerent stages of tumor growth.
As tumor endothelial behavior results from the local pres-
ence of growth factors, cytokines, and other molecules,
which varies during tumor development [8–10], the diﬀer-
ences in angiogenic status would be reﬂected in variations2 ISRN Oncology
in local expression patterns of angiogenesis- and vascular
maturation-related genes during tumor outgrowth. The
basis for rational antiangiogenic therapy regimen design
throughout the diﬀerent stages of tumor growth lies in the
understanding of the nature and location of the expression
of angiogenic genes and local balances thereof in their
pathophysiological environment.
Whileavastnumberofstudiesinvestigatedthemolecular
control of angiogenesis using transgenic animal models that
either overexpress speciﬁc genes or have a full gene knock-
out, only limited studies describe the molecular angiogenic
make up of tumors that is endorsed by endogenously
controlled mechanisms. In the current study we investigated
theangiogenicphenotypeofthewidelyused,subcutaneously
(s.c.) growing mouse B16.F10 melanoma model at an early,
intermediate and late stage of tumor growth. By real-time
RT-PCR, we quantiﬁed the expression of 52 genes that
have previously been reported to be major controllers of
tumor angiogenesis. Based on the morphological diﬀerences
observed, we next zoomed in on the tumor vascular com-
partment by laser microdissection, to obtain a more detailed
view on the localization of angio-gene expression in the
complexity of the in vivo tumor microenvironment. Lastly,
we analyzed a number of vascular features, that is, vascular
morphology, pattern of pericyte association, and prolifera-
tion status of tumor and endothelial cells in the diﬀerent
growth stages, and related them to the observed local gene
expression patterns.
2.MaterialsandMethods
2.1. Tumor Cell Culture and Animal Studies. B16.F10 murine
melanoma cells were cultured in 75cm2 culture ﬂasks in
DMEM (Biowhittaker, Verviers, Belgium) supplemented
with 10% fetal calf serum (FCS; Hyclone, Perbio Science,
Etten-Leur, The Netherlands), 2mM L-glutamine (Biowhit-
taker), and 1% gentamycin (Biowhittaker) at 37◦Ca n d5 %
CO2/95% air in a humidiﬁed incubator.
Male C57bl/6 mice (20–25g; Harlan, Zeist, The Nether-
lands)weresubcutaneouslyinoculatedwith100,000B16.F10
melanoma cells in 100μL phosphate-buﬀered saline under
anesthesia by inhalation of isoﬂurane/O2.T h em i c ew e r e
monitored daily for behavior and every other day for body
weight. Mice were randomly divided into three experimental
groups from which tumors were harvested at three diﬀerent
stages of tumor growth: 25 ± 0.7 (early stage/small volume,
day 9 after tumor inoculation), 182 ± 1.5 (intermediate
stage/volume, day 12–16), and 524 ± 42.3 (late stage/large
volume, day 14–25)mm3.T u m o r sw e r em e a s u r e de v e r y
other day by calipers, and the volume was calculated
according to the formula: tumor volume = 0.52 ∗ length ∗
width2, with “width” being the shorter of the two diameters.
Animals were sacriﬁced under anesthesia by inhalation of
isoﬂurane/O2, and tumors were excised, immediately snap
frozen in liquid N2,a n ds t o r e da t−80◦C until further ana-
lysis.
The animal experiments were approved by the local Ani-
malCareandUseCommitteeoftheUniversityofGroningen.
2.2. Gene Expression Analysis by Quantitative RT-PCR. Ex-
traction of total RNA from cryostat-cut sections of the
tumors was carried out according to the protocol of RNeasy
Mini Plus kit (Qiagen, Leusden, The Netherlands). RNA was
analyzed qualitatively by gel electrophoresis and quantita-
tively by Nanodrop ND-100 spectrophotometry (NanoDrop
Technologies, Rockland, DE, USA) and consistently found
to be intact and protein-free. Total RNA was subsequently
reversetranscribedasdescribedpreviously[11],usingSuper-
script III Reverse Transcriptase (Invitrogen, Carlsbad, CA,
USA) in a 20μL ﬁnal volume containing 250ng of random
hexamers (Promega, Madison, WI, USA) and 40 units
of RNase OUT inhibitor (Invitrogen). mRNA expression
analysis was performed in a real-time PCR-based, custom-
designed, Low-Density Array set-up (Applied Biosystems,
Foster City, CA, USA). The Low-Density Array was designed
with exon-overlapping primers and minor groove-binding
(MGB) probes of 46 genes (see Table 1 in supplemen-
tary material available online at doi:10.5402/2011/409308)
selected for their involvement in angiogenesis, inﬂammation
and basic inﬂuence on endothelial cell behavior, as reported
in the literature [12–19], including GAPDH as a house-
keeping gene. The Low-Density Array card was processed
according to the suppliers’ protocol and analyzed in an ABI
PRISM 7900HT Sequence Detector (Applied Biosystems).
For a selection of genes and for PCNA, the Notch family
genes, αSMA and desmin (see Supplementary Table 1), real-
time PCR was performed in duplicate per sample with
1μL cDNA per reaction in TaqMan PCR MasterMix in
a total volume of 10μL, with primer-probe sets (where
appropriate corresponding to the ones pre-spotted on the
Low-Density Array cards) being purchased as Assay-on-
Demand from Applied Biosystems (Nieuwekerk a/d IJssel,
The Netherlands).
2.3. Laser Microdissection of B16 Tumor Vasculature. Five μm
cryosections mounted on polyethylene-naphtalene mem-
branes attached to normal glass slides (P.A.L.M. Microlaser
Technology AG, Bernried, Germany) were ﬁxed in acetone
and stained with Mayer’s haematoxylin, washed with diethyl
pyrocarbonate-treated water, and air-dried. Tumor vascular
segments (1-2 × 106 μm2 surface area, including vessel
lumen area) of both intermediate and large tumors and
normal mouse kidney postcapillary venule segments (0.6
× 106 μm2) were microdissected using the Laser Robot
Microbeam System (P.A.L.M. Microlaser Technology), yield-
ing isolated vascular tissue from vessels with a clearly visible
lumen. To isolate vascular segments from small proﬁles
that do not contain a visible lumen and are therefore not
identiﬁable based on haematoxylin staining, we applied
ﬂuorescence guidance during laser dissection. Tumor vascu-
lar segments representing small vascular proﬁles and large
lumen-containing vessels were separately microdissected
using an LMD6000 Laser Microdissection system (Leica,
Wetzlar, Germany) from 9μmc r y o s e c t i o n so fl a r g et u m o r s
mounted on polyethylene-terephthalate membranes on steel
frames (Leica) that were stained with FITC-conjugated
Griﬀonia Simplicifolia Lectin I IsolectinB4 (GSLI-isolectin
B4: Vector Labs, Burlingame, CA, USA). The two vascularISRN Oncology 3
morphologies were distinguished based on the combination
of size of the vessel (small versus large) and the absence
respectively presence of a visible lumen.
Total RNA was extracted according to the protocol of
Absolutely RNA Microprep kit (Stratagene, Amsterdam,
The Netherlands) or RNeasy Micro Kit (Qiagen) for hae-
matoxylin-stainedlumen-containingvesselsandﬂuorescent-
stained vascular proﬁles/segments respectively, and reverse
transcribed and analyzed by Low-Density Array and/or
quantitative PCR as described above.
2.4. Immunohistochemical and Immunoﬂuorescent Staining of
Tumor Tissues. Immunohistochemical detection of antigens
(CD31, ICAM-1, VCAM-1, Tie2, and vWF) in acetone-ﬁxed,
5 μm cryostat-cut sections was performed using the Dako
Envision System-HRP kit (Dako Cytomation, Glostrup,
Denmark) according to the suppliers’ protocol. In brief,
after rehydration, sections were incubated with endogenous
peroxidaseblockdiluted 1:1withPBSfor5minutes,washed
withPBSandsubsequentlyincubatedwithprimaryantibody
diluted in 5% FCS in PBS for 60 minutes. The follow-
ing primary antibodies were used: Rat-anti-Mouse CD31
IgG2a (BD Pharmingen; clone MEC13.3), Rat-anti-ICAM-1
IgG2b (YN1/1.7.4 hybridoma supernatant), Rat-anti-Mouse
VCAM-1 IgG2a (BD Pharmingen; clone 429), Rat-anti-Tie2
(eBioscience; clone Tek4), and Rabbit-anti-vWF (Dako). In
case of rat primary antibodies, sections were incubated with
unlabeled Rabbit-anti-Rat IgG diluted 1:500 (H+L, Vector
Labs) for 45 minutes. After incubation with anti-rabbit
HRP-conjugated polymer for 30 minutes, peroxidase activity
was detected with 3-amino-9-ethylcarbazole (AEC) complex
and sections were counterstained with Mayer’s haematoxylin
(Merck, Darmstadt, Germany).
Expression of the nuclear proliferation marker Ki67
was assessed by immunohistochemical staining of acetone-
ﬁxed cryosections. Sections were incubated with rab-
bit monoclonal antibody to Ki67 (Lab Vision, Duiven,
The Netherlands) in 5% FCS/PBS for 60 minutes, after
Avidin/Biotin blocking (Dako). Sections were incubated
with biotin-conjugated Goat-anti-Rabbit immunoglobulins
(Dako) and subsequently incubated with Streptavidin-HRP
(Dako) according to the manufacturers’ protocol. Peroxidase
activity was detected with AEC (Sigma-Aldrich; Steinheim,
Germany) and sections were counterstained with Mayer’s
haematoxylin. Sections were embedded in Kaisers Glycerin
(Merck) and examined using a Leica DMLB microscope and
Leica Qwin V3 software.
The presence of pericytes was visualized by immunoﬂuo-
rescent double staining for α-Smooth Muscle Actin (αSMA)
or desmin with CD31. Five μmc r y o s e c t i o n sw e r eﬁ x e d
with acetone/methanol (1:1) on ice for 5 minutes and
preincubated with PBS supplemented with 1% BSA, 10%
normal goat serum (NGS; Dako), and 0.20% Tween-20 for
30minutesatroomtemperature.Subsequently,sectionswere
incubated with Cy3-conjugated mouse-anti-αSMA (Sigma)
or Rabbit-anti-desmin (Abcam, Cambridge, UK) in the
presence of Rat-anti-Mouse CD31 for 60 minutes at room
temperature. All antibody incubations were performed in
PBS supplemented with 1% BSA, 10% NGS, and 0.20%
Tween-20. Sections were washed with PBS and subsequently
incubated with Alexa ﬂuor 568-conjugated Goat-anti-Rabbit
IgG to detect desmin and Alexa ﬂuor 488-conjugated Goat-
anti-Rat IgG to detect CD31 (both H+L, Molecular Probes
Invitrogen Detection Technologies, Eugene, Oregon). After
washing with PBS, nuclear counterstaining was performed
using DAPI (F. Hoﬀmann-La Roche Ltd, Basel, Switzerland).
Autoﬂuorescence was reduced by incubating the sections in
0.1% Sudan Black (Sigma-Aldrich) in 70% ethanol for 30
minutes at room temperature. Sections were embedded in
Citiﬂuor (Citiﬂuor Ltd., London, UK) and examined using a
ﬂuorescence microscope (DM RXA, Leica) and Leica Qwin
V3 software.
2.5. Statistics. Linear Mixed Eﬀects (LMEs) Models and
Analysis to account for multiple measurements within mice
were used for data analysis to address the signiﬁcance of
observed eﬀects [20]. Multiple testing was controlled by the
step-up False Discovery Rate-controlling procedure of Ben-
jamini and Hochberg [21] in calculating adjusted P values
(Padj < 0.05 indicated statistical signiﬁcance)forthediﬀerent
researchquestions.AllanalyseswereperformedusingR[22].
Statistically signiﬁcant diﬀerences in gene expression
in endothelium of the two diﬀerent vascular morpholo-
gies observed were assessed by means of Student’s t-test
(GraphPad Prism, GraphPad Software, San Diego, CA) and
considered to be signiﬁcant when P<0.05.
3. Results
3.1. Diﬀerent B16.F10 Growth Stages Presented with a Dif-
ferent Vascular Morphology, but with a Similar Gene Ex-
pression Proﬁle. We hypothesized that early-stage tumor
growth would be characterized predominantly by angiogenic
sprouting vasculature, while in late-stage tumors active an-
giogenic vascular sprouts would exist next to “quiescent”
matured neovessels. This would represent one mode of vas-
cular heterogeneity that may aﬀect eﬃcacy of drug treat-
ment. Therefore, we ﬁrst investigated neovessel development
during tumor growth from a morphological point of view
and at a molecular level in s.c. growing B16 tumors, which
were harvested at an early (palpable), intermediate, and late
stage of tumor development (Figure 1).
Vascular morphology changed drastically throughout
tumor development. While palpable tumors were charac-
terized by small vessels, generally containing no or a small
lumen, the vascular network of intermediate and large
tumors consisted of vessels with wide lumen that existed
next to small vascular structures without lumen. The vessels
with the largest lumen surface were found in the large
tumors (Figures 1(a)–1(d)). Strikingly, these morphological
diﬀerences were not accompanied by a major diﬀerence
in angio-gene expression proﬁle (Figure 2), except for the
expression of integrin β3, which was statistically signiﬁcantly
higher in small tumors versus intermediate and large tumors
(P<0.05). Expression of molecules from the VEGF-family
and their receptors, regarded as key regulators of the ﬁrst
step of the angiogenic cascade, was equal in the three stages
of tumor outgrowth. The ratio of Ang2/Ang1 mRNA levels4 ISRN Oncology
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Figure 1: Morphological appearance of tumor vasculature of B16.F10 melanoma growing subcutaneously: immunohistochemical detection
of CD31. Tumors were harvested at three diﬀerent growth stages, based on tumor volumes as depicted in (e) (mean of 3 mice per group ±
SEM). Vascular morphology diﬀered per tumor growth stage, presenting vessels with increasing lumen size in intermediate and large tumors
next to the presence of small vascular proﬁles, while small tumors were characterized by only small vessels that were generally lacking a
visible lumen (Magniﬁcation 100x).
varied between 24 and 78, which is in line with the current
dogma that a dysbalance in Ang2/Ang1 in favor of Ang2 de-
stabilizes the endothelium and presensitizes it for (VEGF-
induced) proliferation and angiogenic sprouting [23].
Low mRNA levels of the adhesion molecules P- and E-
selectin were associated with nondetectable protein levels
(data not shown), while the mRNA expression levels of
VCAM-1 and ICAM-1 were higher and associated with
protein expression restricted to a subset of blood vessels
(Figure 3). ICAM-1 was furthermore expressed by perivas-
cular inﬁltrates of some vessels. Both VCAM-1 and ICAM-
1 expression were more intense in palpable compared to
intermediate and large tumors, a trend also observed at
the ICAM-1 mRNA level that was however statistically not
signiﬁcant. Interestingly, the mRNA level of von Willebrand
Factor, which is like CD31 and VE-cadherin regarded as
an endothelial marker molecule and often used as research
tool for immunoﬂuorescence double staining protocols [24],
was much lower than that of CD31, an observation that
was conﬁrmed at the protein level. In contrast to CD31,
vWF protein expression appeared granular and covered only
parts of the vessel wall of a small subset of vessels. Also
Tie2 expression was detected in a subset of vessels and often
did not fully cover the endothelial lining within the vessel
wall. Both vWF and Tie2 protein expression patterns did not
change during tumor growth.ISRN Oncology 5
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Figure 2: In the three diﬀerent stages of s.c. B16.F10 tumor growth, mRNA expression of the 46 genes under study is similar. Tumors
were harvested at palpable, intermediate, and large volumes (early, intermediate and late stages). Values represent mRNA expression levels
measured by qRT-PCR-based Low-Density Array and adjusted to GAPDH. Mean + SD; n = 3. Expression of FGF-2, FGFR2, Ang1, P-
selectin, E-selectin, and COX-2 was additionally measured twice by manual qRT-PCR. PCNA was measured by manual real-time RT-PCR
alone in duplicate. ∗P<0.05. ND: not detectable.
3.2. Gene Expression in the B16.F10 Tumor Vascular Com-
partment That Represents Lumen-Containing Vessels. We
hypothesized that vascular behavior is the result of locally
controlledbalancesofgeneexpression.Asthemajorityofthe
genes under study are not restricted to the endothelium, we
zoomed in on the local balances of vascular gene expression
by isolating tumor vascular segments from their environ-
ment by laser microdissection prior to gene expression
analysis.
mRNA of microdissected tumor vasculature identiﬁed
by light microscopy in haematoxylin-stained biopsies, hence
representing lumen-containing vasculature, showed a ∼20–
60 fold enrichment in endothelial marker genes CD31, VE-
cadherin, vWF, and EphrinB2, compared to mRNA isolated
from a tumor biopsy as a whole (Figure 4). Moreover, we
couldassignVEGFR1and-R2,FGFR1,Ang2,Tie2,PDGF-B,
PDGF-Rβ, eNOS, t-PA, and Tsp-1 as being tumor vascular-
associatedinthiss.c.B16.F10tumormodel,astheyexhibited
a similar 15–50-fold enrichment. In contrast, FGF-2, FGFR2,
Ang1, MMP2, MMP9, plasminogen, TNFα, P-selectin, E-
selectin, and COX-2 transcripts were not detectable in this
compartment.
Of note is the observation that compartmentalization of
genes revealed that the relative balances of gene expression
in the tumor vasculature diﬀered from those observed when
analyzing the tumor tissue as a whole. For example, when
analyzing the mRNA levels in the tumors, the levels of
integrin β3 were 2.5-fold lower than those of integrin αv,
while in the tumor vasculature both integrin subunits were
expressedatequallevels.Similarly,theratiobetweenthepro-
apoptotic gene Tsp-1 [25] and the antiapoptotic Bcl2 shifted
from1.9inthetumorto13.6inthetumorvasculature,which6 ISRN Oncology
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Figure 3: Vascular localization and expression of endothelial molecules at the protein level in B16.F10 tumors growing at three diﬀerent
stages of tumor growth. Expression of VCAM-1 and ICAM-1 was highest in the early-stage tumors, as compared to intermediate and large
tumors. A granular pattern of vWF expression was found in a small number of tumor vessels; the majority of them were negative for vWF.
Tie2 expression remained the same throughout tumor development and was observed in only a subset of the vessels. The top three and
bottom three rows of panels represent immunohistochemical staining of consecutive sections. Arrowheads point to the structures that are
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Figure 4: Vascular compartmentalization of angio-gene expression in a large tumor. Tumor vasculature was laser microdissected and its
gene expression proﬁle was compared to that of the tumor as a whole. Values represent mRNA levels adjusted to GAPDH. Mean values ±
SD of 3 qPCR analyses, except for CD31, VE-cadherin, vWF, EphrinB2, EphB4, Integrin αv, VEGFR2, Tie2, iNOS, eNOS, TNFα,T N F R 1 ,
TNFR2 (a total of 5 qPCR analyses), and for VEGF (a total of 7 qPCR analyses) and PCNA (qPCR in quadruplicate). ∗P<0.05. ND: not
detectable.
may point to a relatively higher degree of Tsp1-induced
proapoptotic signaling in the tumor vasculature compared
to the non-vascular tumor compartment.
3.3. Diﬀerent Vascular Morphologies Are Associated with a
Similar Proﬁle of Angiogenic Gene Expression. The vascu-
lature of late-stage tumors was characterized by regional
variations in vascular morphology. Regions with small vas-
cular proﬁles present at a high density (Figure 5(a))e x i s t e d
next to regions with large vessels containing a wide lumen
that were distributed at a much lower density (Figure 5(b)).
Based on reports describing a role for HIF-1α and VEGF in
determining blood vessel morphogenesis, including lumen
formation [26, 27], we hypothesized that a diﬀerential pat-
tern of expression of these genes might underlie the diﬀerent
vascular morphologies in this tumor model. To study this,
we separately microdissected large, lumen-containing vessels
and small vascular segments without lumen, guided by ﬂu-
orescence staining with the FITC-labeled GSLI-isolectinB4
(Figures 5(c) and 5(d)). Surprisingly, both vascular mor-
phologieswerecharacterizedbyanidenticalproﬁleofmRNA
expression of those genes that were previously assigned as
major controllers of vascular morphology and structure
(Figure 5(e)). Also mRNA levels of members of the Notch
family of genes and their ligands, which were recently
identiﬁed as being in control of angiogenic sprout formation
(Notch1 and Dll4 [28]) on the one hand, and endothelial-
pericyte adhesion (Notch3 and Jag1 [29]) on the other hand,
did not diﬀer in the two morphologically diﬀerent vascular
segments (Figure 5(f)).8 ISRN Oncology
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Figure 5: Diﬀerent vascular morphologies displayed a similar pattern of gene expression. High variability of vascular morphology was
observed in tumors of large volume. Large lumen-containing vessels ((b, d) vessel lumen size > 25μm )e x i s t e dn e x tt om u c hs m a l l e rb l o o d
vessels that did not contain a visible lumen (a, c). (a, b) Immunohistochemical staining for CD31: pictures represent diﬀerent regions within
thesamelargetumor(Magniﬁcation100x).(c,d)CryosectionsfromlargetumorswerestainedwithGSL-IIsolectinB4:FITCandthediﬀerent
vascular morphologies were separately isolated by laser microdissection along the depicted lines, magniﬁcation 400x. Microdissection of
these diﬀerent vascular phenotypes followed by gene expression proﬁling did not reveal a diﬀerential pattern of mRNA expression of
angiogenesis- and vascular stability-regulating genes (e), nor of the Notch family of genes that has recently been identiﬁed to be important
regulators of both angiogenic sprouting and endothelial-pericyte adhesion (f), but demonstrated that the lumen-containing vessels were
associated with signiﬁcantly higher levels of αSMA mRNA compared to the small vessels without lumen (g). (e)–(g) Mean values + SD of
duplicate qPCR measurements of three large tumors. ND: not detectable. ∗P<0.05.ISRN Oncology 9
3.4. Diﬀerent Vascular Morphologies Were Associated with
Diﬀerent Pericyte Phenotypes. As pericyte coverage can aﬀect
vascular morphology, we next set out to investigate pericyte
marker expression in these two segments. Of the three
markers studied (αSMA, desmin, and NG-2), mRNA levels
of αSMA were found to be more than 3-fold higher in
large lumen-containing vessels compared to small vascular
proﬁles, while the other two genes did not signiﬁcantly diﬀer
(Figure 5(g)). To validate this observation we determined
the extent and pattern of pericyte coverage of these two
vascular proﬁles by immunoﬂuorescent double staining for
CD31 and either αSMA or desmin as pericyte markers.
This demonstrated that lumen-containing B16 tumor vessels
were associated with pericytes that stained positive for both
desmin and αSMA, while the majority of small vessels were
associated with support cells that expressed only desmin.
These protein data corroborated the diﬀerence in mRNA
expressioninthetwomorphologicallydiﬀerentvascularbeds
within the same tumor (Figure 6).
Absence of αSMA was previously shown to be a feature
of a microvasculature that is actively engaging in angiogen-
esis [30, 31]. This implies that αSMA-lacking vessels are
most likely to be found in areas where angiogenesis is a
prerequisite for growth, that is, in areas where tumor cells
are highly proliferative. To address whether such a process
indeed underlies the observed diﬀerences, we assessed the
proliferative activity of endothelial cells of both types of
vascular morphologies, and of their surrounding tumor
cells. While the majority of tumor cells were proliferative
active, Ki67 expression was only sporadically detected in en-
dothelial cells of both the small vascular proﬁles and the
lumen-containing vessels. Ki67 expression by tumor cells,
furthermore, appeared homogeneously distributed through-
out the tumor, irrespective of the stage of tumor growth, and
could not be related to the observed diﬀerences in vascular
morphology nor vascular maturity. Similarly, PCNA mRNA
levels did not diﬀer in small vascular proﬁles compared to
lumen-containing large vessels (data not shown).
3.5. The Gene Expression Proﬁles of the Tumor Vasculatures
Represent an Active, Angiogenic Phenotype: Comparison with
Quiescent Endothelium. To molecularly describe the dif-
ference in phenotype between B16.F10 tumor vasculature
that actively engages in angiogenesis, and quiescent, non-
angiogenic vasculature, we proﬁled the expression of the
angio-genes in normal postcapillary venule endothelium
microdissected from a healthy mouse kidney (Figure 7).
This analysis revealed that integrin β3, PlGF, Nur77, TIMP-
1, and t-PA were absent in the majority of normal healthy
kidney endothelium samples, while being present in the
tumorendothelium. Likewise,VEGFR1,Ang2,TGFβ,eNOS,
and MCP-1 were more frequently detected in the tumor
endothelium as compared to normal kidney endothelium.
On the opposite, EphB4, FGFR1, Tie2, Alk5, TNFR2, and
the adhesion molecules VCAM-1 and ICAM-1 were more
frequently detected and at higher levels in normal kidney
endothelium as compared to tumor endothelium from in-
termediate and large tumors.
4. Discussion
In this study we investigated the angiogenic make-up of
s.c. growing B16.F10 tumors at diﬀerent stages of tumor
growth. We furthermore mapped the molecular angiogenic
make-up of the tumor vascular compartment and related
that to the morphology of the vasculature. Our focus lay
on genes that were previously shown to be responsible for
the induction of angiogenic sprouting and vascular matu-
ration. We showed that, although the vascular morphology
changed dramatically during tumor outgrowth, this was not
associated with major diﬀerences in expression of the 46
genes analyzed. Moreover, morphologically highly diﬀerent
tumor vessels exhibited similar expression proﬁles of the
major angio-genes studied. The expression of αSMA was a
discriminative parameter for large vessels; its high mRNA
levels and clear protein expression in large lumen-containing
vessels contrasted with the much lower mRNA levels and the
absenceofproteininsmallvascularproﬁleswithoutalumen.
This diﬀerence in vascular support cell/pericyte characteris-
tics may underlie the diﬀerence in vascular morphology in
this tumor model; yet the angio-genes accompanying this
phenotype remain until now unknown. We demonstrated
that the 46 genes chosen are associated with the angiogenic
process by comparing their expression in the tumor vascular
compartment with that in a mature vessel of a healthy organ,
which showed that many proangiogenic genes indeed exhib-
ited a gain of function in the tumor vasculature. From this
studyweconcludethatthevasculatureofs.c.B16.F10tumors
continues to actively engage in angiogenesis throughout the
diﬀerent stages of tumor growth. The striking diﬀerences
in vascular morphology between small and large tumors
are associated with a diﬀerence in pericyte activation but
have no direct relation to the transcriptional activity of
the angio-genes analyzed in this study. A similar pattern of
proangiogenic gene expression continues to exist in even
later B16.F10 growth stages (tumor volumes ranging from
461–1409mm3;d a t an o ts h o w n ) .
Our aim was to investigate how in a growing tumor
of a widely employed mouse model the expression of
genes important in the control of the diﬀerent stages of
angiogenesis and vascular maturation would spatiotempo-
rally change with ongoing tumor growth. Surprisingly, our
ﬁndings demonstrated that the B16.F10 tumor does not
change its molecular angiogenic repertoire during tumor
development. This outcome contrasts ﬁndings in a rat C6
glioma model growing in the brain [8]a sw e l la si nm u r i n e
orthotopic KM12SM colon carcinoma growth [9]i nw h i c h
VEGF expression varied during tumor growth progression.
Furthermore, expression of Ang2 has been shown to be
elevated during the early stages of tumor outgrowth in a U-
87MGgliomamodelgrowingintracraniallyinathymicmice,
while being downmodulated once the vascular structures
of the tumor had established, as in the later stages of
tumor outgrowth [32]. The here described elevated levels of
the VEGF-receptors, Nur77, Ang2, and Tie2 in the tumor
vascular compartment compared to the tumor compart-
ment [16, 23], as well as the signiﬁcantly higher level of
PDGF-B, a molecule extensively produced by angiogenic10 ISRN Oncology
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Figure 6: Vessels with diﬀerent morphological appearance are covered with pericytes presenting with a diﬀerent pattern of pericyte marker
expression. (a, b) Immunoﬂuorescent double staining for CD31 (green) and desmin (red) or α-SMA (red) and nuclear counter stain
(DAPI; blue) of a representative tumor from the group of late-stage, large volume tumors (Magniﬁcation 200x). (c) Immunohistochemical
detectionofKi67revealedhomogeneousdistributionofproliferativeactivitythroughoutthewholetumor,inallthreestagesoftumorgrowth
(Magniﬁcation 200x). Arrows point to Ki67-positive endothelial nuclei.
tip cells on a sprouting tip [33], suggest a VEGF/Ang2-
driven proangiogenic phenotype of the B16.F10 model
employed. Moreover, as compared to normal endothelium,
tumor endothelium showed gain of function of numerous
proangiogenicmoleculessuchasintegrinβ3,PlGF,VEGFR1,
Nur77, Ang2, eNOS, TGFβ, MCP-1, TIMP-1, and t-PA,
while loss of function was observed for vessel stability genes
such as Ang1 and Tie2. From this, it can be concludedISRN Oncology 11
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Figure 7: Summary of gain and loss of gene expression in
the B16.F10 tumor vascular compartment of intermediate and
large tumors compared to normal quiescent endothelium: gene
expression in microdissected tumor endothelium from s.c. growing
intermediate and large B16.F10 tumors (a total of 6 animals) and
microdissected kidney venule endothelium from healthy C57bl/6
mice (10 animals). Red: detectable expression in more than 75%
of all analyzed samples; yellow: detectable expression in 25–75%
of all analyzed samples; green: expression of the gene could not be
detectedinthemajorityofthesamples(lessthan25%ofpositivity).
that throughout the growth period studied, the majority of
vessels of B16.F10 tumors remain engaged in the angiogenic
process. Interestingly, the same pattern of proangiogenic
gene expression was found when B16.F10 tumors were
grown in the highly vascularized brain (Supplementary
Figure 1), demonstrating that neither the host environment
where the tumor is growing changes the proangiogenic
molecular repertoire of the tumor vasculature.
Yet, during s.c. B16.F10 outgrowth, the vascular mor-
phology underwent a major shift from small, lumen-less
vessels mainly covered by desmin-positive pericytes to
large lumen-containing vessels mainly covered by pericytes
positive for both αSMA and desmin. Recently, Helfrich et
al. reported that spontaneously arising MT/ret transgenic
melanomas were characterized by a similar distribution of
αSMA- and desmin-positive vessels in relation to vascular
lumen size and density and found that αSMA-covered
large vessels were less sensitive to anti-VEGF therapy [31],
thereby illustrating the consequences of tumor vascular
heterogeneity for the outcome of antiangiogenic therapy. A
similar heterogeneity in vascular morphology as observed
in our study was previously reported by Kashiwagi et al.
in B16.F10 tumors grown in cranial windows. In their
study, changes in vascular morphology could not be related
to transcriptional regulation of 96 angiogenesis-associated
genes, including the Angiopoietins and Tie2, VEGF and
its receptor, and PDGF [34]. Vascular morphology has
previously been shown to be under the control of these
genes, with low VEGF levels resulting in a reduction of
blood vessel lumen size in human gastric TMK-1 tumors
in athymic nude mice [26] and in the chick CAM assay
[27]. In the B16.F10 tumor model in immune-competent
mice employed here, vascular morphology did however not
relate to HIF-1α and VEGF mRNA levels. The expression
levels of the VEGFR2 response gene Nur77 in the three
growth stages as well as in the two diﬀerent tumor vessel
morphologies furthermore corroborate the conclusion that
similar levels of VEGF-activity can exist while vasculatures
are morphologically highly variable. Another set of genes
previously shown to aﬀect vascular morphology includes
Notch and Notch ligand Dll4 [28, 35]. Enhanced Dll4
expressioninxenograftmodelswasassociatedwithincreased
vessel size [36], but in our model, these genes were not
discriminative between small vascular proﬁles and lumen-
containing vessels. From these data it becomes clear that
each preclinical angiogenesis model needs to be appreciated
for its own molecular repertoire underlying angiogenesis
and vascular remodeling and that care should be taken in
extrapolating observations from one model to the other.
Although we did not achieve the broader aim of the
study, that is, identiﬁcation of the molecular nature of tumor
vascular heterogeneity during tumor outgrowth, a number
of issues were revealed that are of relevance when studying
angiogenesis. One important ﬁnding is that vWF expression
showed a remarkable heterogeneity throughout the tumor
vasculature. It was not expressed in a pan-endothelial man-
ner as were CD31 and VE-cadherin. A similar loss of vWF
expression during angiogenesis was reported previously by
usin amousemodelof inﬂammation[37],aswellasbyYano
et al. in biopsies from Non-Small Cell Lung Cancer patients
[38]. The use of vWF as a marker for tumor endothelium,
as is employed in, for example, ﬂuorescent double-labeling12 ISRN Oncology
strategies [24], hence can have important drawbacks. More-
over, as endothelial cells are numerically underrepresented
in a tumor, their molecular proﬁle will be masked in whole
tumor mRNA isolates by that of the dominating tumor
cells. By applying laser microdissection-assisted isolation
of the tumor vasculature prior to transcriptional proﬁling,
we were able to reveal local balances in gene expression
that are controlled by the pathophysiological environment
which would have remained masked when analyzing whole
tumor RNA samples. Although microdissection of tumor
endothelium does not yield a pure endothelial isolate as
visualizedbydetectionofmRNAimpuritiessuchaspericyte-
associated genes NG-2, αSMA, and desmin, judging from
the small enrichment of these molecules relative to that of
CD31andVE-cadherin,theircontributiontothepopulation
of dissected cells is minor.
Our results indicate that B16.F10 melanoma vascular
development is accompanied by major changes in the vas-
cular morphology. This observation has clinical relevance,
as variations in vascular architecture have been described in
biopsies from prostate carcinoma patients with metastasis in
bone, liver, and lymph node [39]. Human clear-cell renal
cell carcinoma is characterized by heterogeneous tumor
vascular behavior, including variations in microvascular
density, endothelial cell proliferation, and expression of
angiogenic growth factors [40]. Together, these examples
emphasize the clinical relevance of the occurrence of het-
erogeneity of tumor vascularization and the need for in-
depth studies on the molecular nature thereof. Ideally, the
technique of sampling tumor vascular segments from the
pathophysiologicalenvironmentwouldallowtomicrodissect
immunohistochemically identiﬁed subsets of pericytes or
endothelial cells that are diﬀerentially activated as observed
by, for example, gain and loss of VEGFR2 and αvβ3. If such
a technique could be combined with genome-wide tran-
scriptional proﬁling, unraveling the true molecular nature
of morphological changes and tumor vascular heterogeneity
would come within reach. Immunoﬂuorescence staining
with the lectin as employed here is a ﬁrst step, as it provides
for the ﬁrst time the opportunity to dissect endothelial cells
that are diﬃcult to visualize, while so far in our hands
antibody-based protocols did not allow for proper visual-
ization with maintenance of RNA integrity. Combination
of laser microdissection with kinome and protein arrays to
detect phosphorylation status of many kinases involved in
angiogenic signaling, for example, VEGFR2, ERK, and Akt,
would furthermore broaden the options to get a clearer view
on the molecular basis of tumor vascular heterogeneity [41];
yet at present this is unfeasible due to the limited amount of
tissue yielded by laser microdissection.
FuturestudiesshouldfocusonanextensionofthemRNA
expression proﬁles in the tumor vascular microenvironment,
onregulationand(posttranslational)modiﬁcationthereofat
the protein level, and on determination of the consequence
of antiangiogenic drug treatment on these parameters. Inte-
grating this knowledge will ultimately contribute to the
establishmentofeﬀectiveantiangiogenictherapyintheclinic
and relevant biomarkers of eﬃcacy.
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